Pulmonary Hypertension (Inhalation or Injectable Medication) Precertification Request Updated Pulmon 2026

Get Form
Pulmonary Hypertension (Inhalation or Injectable Medication) Precertification Request Updated Pulmon Preview on Page 1

Here's how it works

01. Edit your form online
Type text, add images, blackout confidential details, add comments, highlights and more.
02. Sign it in a few clicks
Draw your signature, type it, upload its image, or use your mobile device as a signature pad.
03. Share your form with others
Send it via email, link, or fax. You can also download it, export it or print it out.

How to use or fill out Pulmonary Hypertension (Inhalation or Injectable Medication) Precertification Request Updated Pulmon

Form edit decoration
9.5
Ease of Setup
DocHub User Ratings on G2
9.0
Ease of Use
DocHub User Ratings on G2
  1. Click ‘Get Form’ to open it in the editor.
  2. Begin by entering the start date of treatment and the date of the last treatment in the designated fields. Ensure these dates are accurate for proper precertification review.
  3. Fill out the patient information section, including first name, last name, address, and contact numbers. This information is crucial for identifying the patient.
  4. In the insurance information section, provide details such as Aetna Member ID and group number. If applicable, indicate if there is other coverage.
  5. Complete the prescriber information with details about the prescribing physician, including their name, contact information, and specialty.
  6. For dispensing provider/administration information, select where the medication will be administered and provide relevant contact details.
  7. In the product information section, specify which medication is being requested along with dosage and frequency.
  8. Finally, ensure all clinical information is filled out completely to support your request. This includes documenting symptoms and any relevant tests performed.

Start using our platform today to streamline your form completion process for free!

See more Pulmonary Hypertension (Inhalation or Injectable Medication) Precertification Request Updated Pulmon versions

We've got more versions of the Pulmonary Hypertension (Inhalation or Injectable Medication) Precertification Request Updated Pulmon form. Select the right Pulmonary Hypertension (Inhalation or Injectable Medication) Precertification Request Updated Pulmon version from the list and start editing it straight away!
Versions Form popularity Fillable & printable
2019 4.8 Satisfied (65 Votes)
2016 4 Satisfied (41 Votes)
be ready to get more

Complete this form in 5 minutes or less

Get form

Got questions?

We have answers to the most popular questions from our customers. If you can't find an answer to your question, please contact us.
Contact us
The cost of sotatercept is estimated at $25,000 to $30,000 per month. CVS Caremark has a range of solutions to help payors manage the costs of PAH treatment while ensuring that patients receive the right drug at the right time. The anticipated FDA review date is March 2024.
Winrevair is a biologic drug designed to grab onto and trap proteins called activins that are overproduced in PAH. These proteins cause the walls of a persons blood vessels to keep growing and thicken over time. As the blood vessels narrow, the heart is forced to work harder to pump blood to the lungs.
TYVASO is inhaled directly to the lungs, where its neededand may give you the ability to walk farther and do more of what matters most to you. TYVASO is offered in 2 delivery options: a dry powder inhaler (DPI) and a nebulizer.
A new drug from Merck known as WINREVAIR (sotatercept-csrk), was approved by the Food and Drug Administration this past spring.
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved sotatercept-csrk (U.S. Brand Name: WINREVAIR, for injection, 45mg, 60mg) for the treatment of adults with pulmonary arterial

Security and compliance

At DocHub, your data security is our priority. We follow HIPAA, SOC2, GDPR, and other standards, so you can work on your documents with confidence.

Learn more
ccpa2
pci-dss
gdpr-compliance
hipaa
soc-compliance
be ready to get more

Complete this form in 5 minutes or less

Get form

People also ask

The FDA approved sotatercept in March under its expedited approval process after determining sotatercept was a breakthrough drug that could be a docHubly better treatment for a life-threatening condition such as pulmonary arterial hypertension. The conditions name is sometimes shortened to PAH.
The drug has been approved by the FDA for the treatment of adults with PAH (WHO Group 1 pulmonary hypertension) to increase exercise capacity, improve WHO FC, and reduce the risk of clinical worsening events.

Related links